Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Iclaprim vs. vancomycin results published in peer-reviewed journal
February 2018
SHARING OPTIONS:

NEW YORK—Biopharmaceutical company Motif Bio plc recently shared news that results from its Phase 3 REVIVE-1 clinical trial were published in Clinical Infectious Diseases. The trial evaluated iclaprim in patients with acute bacterial skin and skin structure infections compared to vancomycin. In the intent-to-treat population, 80.9 percent of patients receiving iclaprim and 81 percent of patients receiving vancomycin reached the primary endpoint of early clinical response (ECR)—a greater than or rqual to 20-percent reduction in lesion size compare with baseline—at the early time point (ETP) of 48 to 72 hours after the start of dosing. Of the diabetic study participants, 80 in the iclaprim group and 74 percent in the vancomycin group achieved ECR at ETP, and of the patients with moderate/severe renal impairment, 83 percent of iclaprim patients and 75 percent of vancomycin patients achieved ECR at ETP. Iclaprim was also well tolerated.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.